FAQ
…can do so in the resting room placed in the basement of the E-building. Please ask at the reception for further directions. How are Standard access proposals reviewed at MAX…
…can do so in the resting room placed in the basement of the E-building. Please ask at the reception for further directions. How are Standard access proposals reviewed at MAX…
…(See: https://www.maxiv.lu.se/users/proposal-calls/) Most of the beamlines at MAX IV Laboratory are oversubscribed, so proposals should be compelling and carefully written in order to be chosen by the advisory committee. If access…
…a strong and successful LDM community has been active at the lab since its inception. A variety of cutting-edge spectroscopic methods are essential to the work of our LDM community…
…in an efficient and sustainable manner, one that does not rely on fossil sources? Syngas and synthetic fuels The research company Syngaschem BV believes that synthetic fuels can be the key to…
The fluid in your gastrointestinal tract is a complex soup of biomolecules. When you take a pharmaceutical drug, the biomolecules may stick to its surface and alter how it’s dissolved…
…“This, in combination with the high prevalence of organic iron complexes, suggest that the rising iron concentrations in rivers may result in more iron reaching the open waters of the…
…what substrates are relevant to test activity on, where small model compounds do not properly mimic the more complex cell wall,” said Johan Larsbrink, study researcher and associate professor of molecular…
…by the PRISMAS management team based on expertise and experience. The list of selected eligible candidates is handed to the Local Evaluation Committee at the respective university. The committee invites the candidates to a first online interview. As the main Principal Investigator of the…
…used X-ray absorption spectroscopy techniques (XANES and EXAFS) at the Balder beamline at MAX IV. Cobalt-toughened cemented carbide inserts coated with a TiAlN compound were prepared as samples. Each contained…
…point. However, current commercial Keap1-targeting drugs covalently inhibit Keap1, a mechanism of action that comes with a lack of selectivity, side effects, and other complications during drug development. “Through this…